364 related articles for article (PubMed ID: 16513445)
1. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
[TBL] [Abstract][Full Text] [Related]
2. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
[TBL] [Abstract][Full Text] [Related]
3. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats.
Oswald S; Westrup S; Grube M; Kroemer HK; Weitschies W; Siegmund W
J Pharmacol Exp Ther; 2006 Sep; 318(3):1293-9. PubMed ID: 16772539
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
5. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
Oswald S; Meyer zu Schwabedissen HE; Nassif A; Modess C; Desta Z; Ogburn ET; Mostertz J; Keiser M; Jia J; Hubeny A; Ulrich A; Runge D; Marinova M; Lütjohann D; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2012 Mar; 91(3):506-13. PubMed ID: 22297387
[TBL] [Abstract][Full Text] [Related]
6. Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats.
Oswald S; May K; Rosin J; Lütjohann D; Siegmund W
J Pharm Sci; 2010 Jan; 99(1):422-9. PubMed ID: 19504475
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
8. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.
Fahrmayr C; König J; Auge D; Mieth M; Fromm MF
Br J Pharmacol; 2012 Mar; 165(6):1836-1847. PubMed ID: 21923755
[TBL] [Abstract][Full Text] [Related]
9. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
Oswald S; König J; Lütjohann D; Giessmann T; Kroemer HK; Rimmbach C; Rosskopf D; Fromm MF; Siegmund W
Pharmacogenet Genomics; 2008 Jul; 18(7):559-68. PubMed ID: 18551036
[TBL] [Abstract][Full Text] [Related]
10. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice.
Oswald S; Koll C; Siegmund W
J Pharm Sci; 2007 Dec; 96(12):3478-84. PubMed ID: 17828742
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine.
Brueck S; Bruckmueller H; Wegner D; Busch D; Martin P; Oswald S; Cascorbi I; Siegmund W
Mol Pharm; 2019 Sep; 16(9):3823-3830. PubMed ID: 31361500
[TBL] [Abstract][Full Text] [Related]
12. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
13. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats.
Yamamoto T; Ito K; Honma M; Takada T; Suzuki H
Drug Metab Dispos; 2007 Sep; 35(9):1455-8. PubMed ID: 17567728
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
Hardwick RN; Fisher CD; Street SM; Canet MJ; Cherrington NJ
Drug Metab Dispos; 2012 Mar; 40(3):450-60. PubMed ID: 22112382
[TBL] [Abstract][Full Text] [Related]
16. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.
Oswald S; Nassif A; Modess C; Keiser M; Ulrich A; Runge D; Hanke U; Lütjohann D; Engel A; Weitschies W; Siegmund W
Clin Pharmacol Ther; 2011 Apr; 89(4):524-8. PubMed ID: 21368751
[TBL] [Abstract][Full Text] [Related]
18. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.
Bae JW; Choi CI; Lee JH; Jang CG; Chung MW; Lee SY
Eur J Clin Pharmacol; 2011 Jan; 67(1):39-45. PubMed ID: 20865252
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals.
Berlin S; Spieckermann L; Oswald S; Keiser M; Lumpe S; Ullrich A; Grube M; Hasan M; Venner M; Siegmund W
Mol Pharm; 2016 Mar; 13(3):1089-99. PubMed ID: 26808255
[TBL] [Abstract][Full Text] [Related]
20. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2.
de Waart DR; Vlaming ML; Kunne C; Schinkel AH; Oude Elferink RP
Drug Metab Dispos; 2009 Aug; 37(8):1698-702. PubMed ID: 19443695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
